Allowing Greater Access to Safe and Effective Contraception Act

HR8083, titled the "Allowing Greater Access to Safe and Effective Contraception Act," was introduced in the House of Representatives on March 25, 2026, by Rep. Hinson (R-IA-2) with three cosponsors. The bill has been referred to the Committees on Energy and Commerce, Ways and Means, Natural Resources, and Armed Services. This referral to multiple committees indicates an early stage in the legislative process, requiring each committee to consider provisions within its jurisdiction. The bill's primary mechanism is to direct the Secretary of Health and Human Services to give priority review to supplemental applications for oral contraceptive drugs intended for routine use, specifically excluding emergency contraceptives or drugs approved for induced abortion. It also waives associated fees for these applications. The goal is to make these drugs available over-the-counter for individuals aged 18 and older. For individuals under 18, these drugs would remain prescription-only. Additionally, the bill directs the Comptroller General of the United States to conduct a study on Federal funding of contraceptive methods. There is no explicit funding amount authorized or appropriated within the text of this bill; its impact is primarily regulatory and procedural. Structural beneficiaries of this bill, should it advance, would be pharmaceutical companies that manufacture oral contraceptive drugs, as the bill aims to streamline the regulatory pathway for over-the-counter availability. This could potentially expand the market for these products by removing prescription barriers for adults. The bill does not specify any direct procurement or grant mechanisms, focusing instead on regulatory relief and market access. Given the early stage of the bill and the lack of specific market data, no immediate stock price movements can be attributed. The legislative process for HR8083 is in its initial phase, having just been introduced and referred to committees. The multiple committee referrals suggest a complex path forward, as each committee will need to review and potentially mark up the bill. The next steps would involve committee hearings and potential votes before it could be considered by the full House. As of today, 2026-04-09, no further actions have been recorded since its introduction and referral on March 25, 2026.